Sanofi HIMALAYA study SAR443820 RIPK1 inhibitor
The Sanofi study, Himalaya, is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to assess the efficacy and safety of SAR443820 in adult participants with Amyotrophic Lateral Sclerosis.
SAR443820 is an experimental drug being developed by Sanofi Aventis Research and Development to slow the disease progression of ALS by acting on a protein in cells (RIPK1) involved in the regulation of inflammation and cell death.
The study drug comes as a tablet containing 20 mg of SAR443820 or as a corresponding placebo. You will take your tablet twice daily, one in the morning and one in the evening, around the same time each day with a glass of water.
Study consists of part A and part B.
- Part A is the 24-week double-blind placebo-controlled period.
- Part B is the open-label period for up to 1.5 years.
Only after the screening visit will it be clear whether further participation is possible.
More info about this study can be found on the website clinicaltrials.gov or clinicaltrialsregister.eu
Interested, or desire further information? Contact us at onderzoek@als.be
